← All trials
NCT04716114
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 24, 2021
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jan 20, 2021
- Last posted
- Nov 2, 2021
- Enrollment
- 315
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.